CN107299089B - A kind of oxalate oxidase great-hearted under physiological ph conditions and its application - Google Patents
A kind of oxalate oxidase great-hearted under physiological ph conditions and its application Download PDFInfo
- Publication number
- CN107299089B CN107299089B CN201710607474.6A CN201710607474A CN107299089B CN 107299089 B CN107299089 B CN 107299089B CN 201710607474 A CN201710607474 A CN 201710607474A CN 107299089 B CN107299089 B CN 107299089B
- Authority
- CN
- China
- Prior art keywords
- leu
- val
- ala
- oxalate oxidase
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
- C12Y102/03004—Oxalate oxidase (1.2.3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention provides a kind of oxalate oxidase great-hearted under physiological ph conditions and its applications.For its gene order as shown in SEQ ID NO.3, amino acid sequence belongs to gene engineering technology field as shown in SEQ ID NO.7.20% of Rate activity of oxalate oxidase under the conditions of pH7.4 not less than its maximum Rate activity, therefore, drug containing oxalate oxidase can be made injection or embed through enteric material, provide possibility to research and develop a kind of recombination oxalate oxidase drug suitable for treating the excessive disease of oxalic acid.The drug of the oxalate oxidase preparation prevention excessive disease of oxalic acid also can be used in the present invention.
Description
Technical field
The present invention relates to the albumen of a kind of oxalate oxidase gene great-hearted under physiological ph conditions and its coding with answer
With more particularly to the oxalate oxidase reduce oxalosis disease patient blood or oxalate crystal growth in healthy urine concentration being used to prepare
Application in drug belongs to gene engineering technology field.
Background technique
Stone in urinary system disease is the Major health disease in a kind of global range, and most stone in urinary system are by oxalic acid
Calcium or calcium oxalate and phosphoric acid calcium component form.Many diseases are excessively high related with the intracorporal oxalic acid amount of people, such as primary top grass
Excessively caused advanced stage kidney stone disease, cardiac conduction hinder for Aciduria, the second hyperoxaluria, autism, Vulvodynia, oxalic acid
Hinder, Chron disease, inflammatory bowel disease, colitis, urinary calculus, asthma, chronic obstructive pulmonary disease, fibromyalgia,
Zellweger syndrome etc. and other chronic diseases.Primary hyperoxaluria (primary hyperoxaluria, PH)
Including I type, II type and type III are all glyoxylate metabolic disorder genetic disease caused by extremely rare gene mutation, the disease
The missing of specific metabolic enzyme leads to oxalic acid building up in vivo in cause of disease liver: I type disease is because of glyoxylate transamination
Enzyme missing causes, and II type disease is because glyoxalic acid/hydroxypyruvate reductase missing causes, and type III disease is because of the distinctive line of liver
Plastochondria enzyme 4- hydroxyl -2- oxygen-glutaraldehyde contracting enzyme missing causes, and there are also the primary hyperoxaluria diseases of some non-three of the above types
Disease, reason is just in further research.Primary hyperoxaluria disease is a kind of hereditary disease very serious, patients with terminal
Intracorporal blood medium-height grass acid concentration is much higher than normal person's oxalic acid level (< 5 μm of ol/L), up to 100 μm of ol/L along with patient's kidney
The failure of function, oversaturated calcium oxalate can deposit formation in kidney, thyroid gland, myocardium, bone, skin, blood vessel and eye
Calculus damages human body vitals, threat to life.Second hyperoxaluria (secondary hyperoxaluria, SH) is one
The food-borne oxalic acid excessive resorption of kind eats disease caused by a large amount of oxalic acid precursors, caused by reason includes enterogastric diseases, such as
Enteritis, cystic fibrosis, short bowel syndrome are rich in oxalic acid food or oxalic acid precursor preferred diet.Second hyperoxaluria
It is a kind of very common disease, the no primary hyperoxaluria of harm is serious, but high blood oxalic acid and urine concentration of oxalic acid
Still chronic disease caused by patient can be allowed to suffer from oxalic acid excessively or advanced stage urinary tract system failure.
Human body is differed by 10~70% that the oxalic acid of food-borne absorption accounts for uropoiesis total oxalate, and the oxalic acid in food can be with
It is absorbed by entire pipe intestinal digesting system, including stomach, small intestine and large intestine, therefore removes food in digesting and assimilating system organ
In oxalic acid can effectively prevent oxalic acid and absorbed by gastrointestinal tract.Industry generally acknowledges, the excessively high calculus that will lead to of oxalic acid calcium concentration
It is formed, therefore, the concentration for reducing oxalic acid helps to reduce the risk of calculus.
The chronic renal failure (CRF) and renal failure advanced stage (ESRF) patient for needing to dialyse for a long time are also held very much
Easily lead to oxalosis.The renal function missing of such patient causes oxalic acid that can not be removed efficiently, while needing in dialysis procedure
Vitamin C is injected as anti-oxidation medicine, and it can be metabolized in human body and be converted into oxalic acid.In such blood in patient body
Oxalic acid is generally in 30-90 μm of ol/L.2006 annual datas show that the U.S. has 340,000 people to need to dialyse every year, and the number is also always
Rise, therefore, such patient is also among the risk for suffering from the excessive disease of oxalic acid.
Zellweger syndrome (ZSD) patient also excessively has with oxalic acid very high relevance (83%), and ZSD is a kind of mistake
Disease caused by oxide enzyme lacks, although the mechanism of patient's ZSD Oxalate metabolism exception is unclear, ZSD is in patient body
Blood concentration of oxalic acid and primary hyperoxaluria patient be much the same.
It is lithogenous that oxalosis patient's shape can be significantly reduced almost without effective remedy measures so far
Risk, wherein the main certain methods used limit food merely by oral oxalate-degrading enzyme or oxalate degrading bacteria
The absorption of object mesoxalic acid.However, these methods can all encounter a common challenge, that is, the highly acid in gastric environment adds
The pepsin of high vigor can degrade oxalate-degrading enzyme albumen, and trypsase and chymotrypsin in enteron aisle can also degrade oxalic acid drop
Solve enzyme.Moreover, the optimum pH of most known oxalate-degrading enzyme is faintly acid, so in the enteron aisle of neutral meta-alkali
Debility or vigor are very low.Oral oxalic acid decomposed bacteria equally encounters the challenge of the strong acid environment of stomach and the proteolysis of enteron aisle, nothing
Method forms dominant microflora and plays drop oxalic acid effect.
There are mainly two types of oxalate-degrading enzymes in nature: oxalate decarboxylase and oxalate oxidase (www.brenda-
Enzymes.org/), however not being found a kind of oxalate decarboxylase has degradation oxalic acid vigor in physiological environment (pH7.4).The
Once there is the albumen of oxalate oxidase vigor from barley by clearly verifying, play an important role in Barley Seeds during Germination,
Therefore the germinal protein that is otherwise known as (germin protein).Similar (the germ- of the germinal protein once reported in all documents
Like) oxalate oxidase has the vigor of degradation oxalic acid in acid condition.Have article (Biochem.J., 1962,85,
33) report Bougainvillea spectabilis blade has oxalate oxidase vigor under the conditions of pH7.4, but it extracts solution and does not have oxalate oxidase living
Power.Report has great-hearted oxalate oxidase under pH > 7, and amino acid sequence is unknown, the description of WO2011/066282 patent
A kind of enzyme of oxalate-degrading enzyme in fungi, patent Example 5 is not purified out, without any sequence yet
Information, inventor herein also once attempts to purify the enzyme, but does not succeed.Makoto K et al. also once delivered an article
(Journal of the Institute of Brewing, vol 115,2009,232-237) says it from one in article
The oxalate oxidase of kind barley seed and fructus hordei germinatus is vibrant under neutral ph.But inventor herein extracted identical kind
Barley in oxalate oxidase, it is found that it has no oxalate oxidase vigor in pH7.4.Therefore, it finds under physiological ph conditions
Great-hearted oxalate oxidase, and its amino acid sequence is obtained, realize that genetic engineering recombinant expression, industrialized production utilize it
The remedy measures for reducing the oxalic acid content in human body are still very important.
Summary of the invention
In order to overcome the shortcomings in the prior art, the application has screened thousands of kinds of plant samples, tests it in physiological pH item
Whether there is oxalate oxidase vigor under part (pH7.4), screens beet stem, banana skin, Bougainvillea spectabilis, cordate telosma, four-o'clock, house lizard
Wood, candidate's species such as manioca, the gene order of coding oxalate oxidase is then cloned by gene cloning means, passes through base
Because engineering recombinant expression system (Escherichia coli, Pichia pastoris, tobacco and pea) recombinantly expresses, the correctness of gene order is verified
And the vigor property of its oxalate oxidase.
The present invention provides one group under the conditions of 7.4 pH great-hearted oxalate oxidase, can degrade oxalic acid or oxalic acid
Salt, the consistency of any one of gene order and SEQ ID NO.1-4 at least 50%.
The present invention provides one group under the conditions of 7.4 pH great-hearted oxalate oxidase, can degrade oxalic acid or oxalic acid
Salt, any one of gene order and SEQ ID NO.1-4 at least 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 98%, 99%, 100% consistency.
It is a further object to provide one group under the conditions of 7.4 pH great-hearted oxalate oxidase, can degrade
Oxalic acid or oxalates, the consistency of any one of amino acid sequence and SEQ ID NO.5-8 at least 50%.
The present invention also provides one group under the conditions of 7.4 pH great-hearted oxalate oxidase, can degrade oxalic acid or oxalic acid
Salt, any one of amino acid sequence and SEQ ID NO.5-8 have at least 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 98%, 99%, 100% consistency.
The above oxalate oxidase can be from beet stem, banana skin, Bougainvillea spectabilis, cordate telosma, four-o'clock, house lizard wood, manioca
It extracts and obtains in equal plant species.
The present invention also provides one group under the conditions of 7.4 pH great-hearted oxalate oxidase, can degrade oxalic acid or oxalic acid
Salt is the polyethyleneglycol modified oxalate oxidase with different molecular weight.
The molecular weight of the polyethylene glycol is 2kD, 5kD, 10kD, 20kD, 4 arm -20kD, 30kD, 40kD or 4 arms -
Any one in 40kD.
The present invention provides a kind of expression vector comprising oxalate oxidase gene, wherein oxalate oxidase gene sequence with
The consistency of any one of SEQ ID NO.1-4 at least 50%.
The present invention provides a kind of expression vector comprising oxalate oxidase gene, wherein oxalate oxidase gene sequence with
Any one of SEQ ID NO.1-4 at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98%, 99%, 100% consistency.
The present invention provides a kind of recombinant expression strain, includes the above expression vector, and can generate oxalate oxidase.
The present invention provides a kind of genetically modified plants strain, Activities of Some Plants (including blade, root are spent) or plant cell, turn
Change has the expression vector containing the above oxalate oxidase gene sequence.
The present invention also provides the oxalate oxidases to reduce the drug of oxalosis disease patient concentration of oxalic acid in preparation
In application.The oxalosis disease includes primary hyperoxaluria, two type hyperoxalurias, zellweger disease,
Or chronic urinary system damageability disease etc..
Since the oxalate oxidase has enzyme activity under the conditions of 7.4 pH, the drug containing oxalate oxidase can be with
Injection is made or is embedded through enteric material.
One group of oxalate oxidase provided by the invention, its Rate activity under the conditions of pH7.4 is not less than its maximum Rate activity
20%, and its be uniquely being disclosed of finding up to now and what is be verified have work in pH7.4 or pH7.0~8.0
The oxalate oxidase of power.A kind of recombination oxalic acid oxygen suitable for treating the excessive disease of oxalic acid is researched and developed in being found to be for the oxalate oxidase
Change enzyme drug and provides possibility.The drug of the oxalate oxidase preparation prevention excessive disease of oxalic acid also can be used in the present invention.
Detailed description of the invention
Fig. 1 is yeast expression vector Z α -5102 map.
Fig. 2 is yeast expression vector GAPZ α -5102 map.
Fig. 3 is yeast expression vector Z α -5601 map.
Fig. 4 is yeast expression vector GAPZ α -5601 map.
Fig. 5 is yeast expression vector Z α -30640 map.
Fig. 6 is the expression that SDS-PAGE analyzes Pichia pastoris X33 medium-height grass acid oxidase Z α -5102.
Fig. 7 is the expression that SDS-PAGE analyzes Pichia pastoris X33 medium-height grass acid oxidase Z α -5601.
Fig. 8 is the expression that SDS-PAGE analyzes Pichia pastoris X33 medium-height grass acid oxidase Z α -30640.
Fig. 9 is the expression that SDS-PAGE analyzes Pichia pastoris X33 medium-height grass acid oxidase GAPZ α -5601.
Figure 10 is plant expression vector map.
Figure 11 is the colour developing of tobacco leaf mesoxalic acid oxidase.
Figure 12 is oxalate oxidase viability examination, pH 7.4.
Contain 2mM oxalic acid in the test tube of left side, is free of oxalic acid in the test tube of right side.
Figure 13 is influence result figure of the oxalate oxidase of different molecular weight PEG modification in rat model to blood oxalic acid.
Figure 14 be different molecular weight PEG modification oxalate oxidase in rat model to urine oxalic acid influence result figure.
Figure 15 is that SD rat, antibody is immunized in the B5102 sample that oxalate oxidase B5102 and different molecular weight PEG is modified
Potency result figure.
Specific embodiment
The present invention is further illustrated below by the mode of embodiment, but does not therefore limit the present invention to the reality
It applies among a range.In the following examples, the experimental methods for specific conditions are not specified, according to conventional methods and conditions, or according to quotient
The selection of product specification.
[embodiment 1] produces the screening of oxalate oxidase plant and vigor is tested
Inventor herein is from Medicinal Plants of Guangxi garden, Kunming botanical garden, plants in Wuhan Botanical Garden and extra large Subtropical Botanical Garden
Over thousands of kind of plant sample is acquired, the screening experiment of oxalate oxidase is carried out.
When producing oxalate oxidase foliage filter screening, sample first passes through processing, and treatment process is as follows: by a certain amount of plant sample
(leaf, root, stem or flower) is shredded with scissors, is put into the quantitative beaker for filling pure water, is suspension with high-shear homogenizer homogenate
(particle < 100 μm), homogenate are divided into soluble fraction (supernatant) and insoluble part (precipitating), insoluble part after being centrifuged
It is resuspended with pure water, the two is respectively intended to survey the vigor of degradation oxalic acid.
Oxalate oxidase vigor test method has following two:
(1) HPLC method: the oxalic acid solution (being adjusted to pH 7.4 with NaOH) of the 12mM of 40 μ l samples and 360 μ l is taken to mix
Afterwards, it reacts 48 hours for 37 DEG C, reaction solution adds terminate liquid (100 μ l 1.5M sulfuric acid solution) to terminate reaction.Reaction solution is through high speed centrifugation
Removal precipitating, supernatant are crossed after 0.4 μm of film and measure oxalic acid content with HPLC.One enzyme-activity unit is defined as every in the above system
Minute reduces enzyme amount required for 1 micromole's oxalic acid.
(2) development process surveys oxalate oxidase vigor:
20 μ l sample solutions and 580 μ l vigor developing solutions (contain 10mM oxalic acid;The chloro- 2- hydroxy benzene sulfonic acid of 4mM 3,5- bis-
Sodium (DHBS);The horseradish peroxidase of 2U;The 4-AA (4-AA) of 1mM;The phosphate buffer of 50mM, pH6.0
Or 7.4), 37 DEG C of reaction 30min monitor OD with microplate reader492Absorbance.One enzyme-activity unit is defined as in above-mentioned reactant
Enzyme amount required for 1 micromole's oxalic acid is reduced in system per minute.
By screening, it has been found that banana skin (banana peel), beet stem (beet stem), Bougainvillea spectabilis blade
(Bougainvillea spectabilis leaves), four-o'clock tender shoots (Mirabilis jalapa young leaf), night
Come spiceleaf piece (Telosma cordatum (Brum.f.)), manioca blade (Jatropha carcas L.leaf), house lizard wood
Plant samples such as (Sauropus androgynus (L.) leaf) have specific oxalate oxidase vigor in the environment of pH7.4.
The clone of [embodiment 2] banana and beet oxalate oxidase gene
(1) oxalate oxidase crude product is extracted in beet stem and banana skin sample
A certain amount of beet stem and banana skin sample are weighed, is put into the beaker for filling pure water after chopping, through high-speed homogenization
Machine homogenate is particle less than 100 μm, centrifugation removal supernatant (debility or extremely low oxalate oxidase vigor), and precipitating is with containing
The buffer solution (2mM PBS, pH7.0) of surfactant (1% thiosulfonic acid NaTDC) and sucrose (50%w/v) is resuspended
Afterwards, it extracting 2~5 days for 4 DEG C, the crude extract of oxalate oxidase collects elution samples peak through Q-sepharose chromatography, after
The surfactant and salt component in sample are removed through dialysis.Oxalate oxidase sample still has after Native-PAGE is separated
Oxalate oxidase activity, by identifying sample elution peak and oxalic acid oxygen after the oxalate oxidase vigor colour developing of Native-PAGE glue
Change enzyme band, after the separation of SDS-PAGE glue, after oxalate oxidase band is cut in the analysis test of commission China Agricultural University
The heart does nitrogen end (N-terminal) amino acid sequencing and the analysis of MS-MS mass spectrum sequence.
(2) genome sequence is retrieved
According to N-terminal sequencing result, by the protein sequence of nitrogen end in the banana announced and the open gene of beet
T-blastn retrieval is carried out in group sketch, candidate gene order is obtained, is then compared with mass spectrographic the sequencing results,
Determine target oxalate oxidase gene sequence.
(3) gene cloning
Special primer (table 1) is designed according to fixed oxalate oxidase gene DNA sequence dna, in banana and the cDNA of beet
PCR amplification is carried out in library, whether sequencing identification is cloned into oxalate oxidase gene after PCR product is carried out purification and recovery.This
Experiment is cloned into B5100, B5102, B5601 from beet altogether, oxalate oxidases candidate's base such as M30640 from banana
Because of (as shown in SEQ ID NO.1-4).Also it is cloned into a plurality of germin-like gene order simultaneously: 108,122,303,
1013 (as shown in SEQ ID NO.9-12).
1 oxalate oxidase cloning primer of table
PCR system (50 μ l):
PCR program:
[embodiment 3] E. coli system expression recombination oxalate oxidase
(1) building of plasmid
Oxalate oxidase (OxOx) B5100, B5102, B5601, M30640 gene cloning is built into pAT carrier (load
Body is derived from pET-32a carrier), recombinant plasmid is then transferred to E.coli Origami B competent cell.
(2) shaking flask is expressed in a small amount
By B5100, B5102, B5601, the glycerol strain of M30640 is coated on LB agarose plate (containing 100 μ g/ml ammonia benzyls
Antibiotic), 37 DEG C of inversion overnight incubations to have monoclonal bacterial plaque appearance.Picking single colonie is inoculated in 200ml Shake flask medium
(culture medium of LB containing 50ml, 100 μ g/ml ammonia benzyl antibiotic), 220rpm, 37 DEG C of cultures, OD600To 0.6~0.8, MnCl is added2
The final concentration of 0.6mM of final concentration of 1mM, IPTG carries out inducing expression, and after inducing 5h, 9500g is centrifuged 15min and collects thallus, bacterium
Weight is suspended from 50mM arginine solution, and ice-bath ultrasonic is crushed 30min, and washing 2 times is resuspended with 50mM arginine, in inclusion body
Having 80% is oxalate oxidase albumen.Thallus yield is under the fermentation condition up to 0.2~0.6g/L.
(3) 7L fermentor great expression
By B5100, B5102, B5601, M30640 gene monoclonal bacterial plaque accesses (the LB culture containing 200ml of 500ml shaking flask
The ammonia benzyl antibiotic of base and 100 μ g/ml), it is incubated overnight, as seed liquor.Seed liquor is accessed 7L's by 0.5% inoculum concentration
Fermentor (the basal medium containing 3.5L: glycerol 12g/L;Yeast powder 12g/L), 200rpm, 37 DEG C of cultures, 10% ammonium hydroxide tune
It saves pH to stablize after 6.85, about 8h, starts at the uniform velocity to add supplemented medium (30g/L glycerol, 60g/L yeast powder), work as OD600It reaches
When to 20, IPTG to final concentration of 0.8mM is added, continues to induce 20h, tank is put and collects thallus.Thallus yield is in the fermentation condition
Lower reachable 1~5g/L.
(4) inclusion body protein washing and renaturation
Inclusion body washing:
Coli somatic cell washing buffer (50mM Tris, 50mM NaCl, 5mM EDTA, 5mM
DTT, 1%TritonX-100,2M urea are resuspended with hydrochloric acid tune pH8.0), and nuclease then is added according to 1:1000
(Benzonase, the MgCl containing final concentration of 0.5mM2), 15min is stirred, the thinning laggard horizontal high voltage homogeneous of bacterium solution is high-pressure homogeneous
Condition be 1100bar, repeatedly be crushed 4 times.Clasmatosis liquid is subjected to 8000g and is centrifuged 10min, abandons supernatant, collects inclusion body
Precipitating.Inclusion body is sufficiently resuspended with suitable wash buffer, and stir about 30min, 8000g are centrifuged 10min, is abandoned supernatant and is collected
Precipitating washs repeatedly and inclusion body is resuspended with pure water afterwards three times, and 8000g is centrifuged 10min after being sufficiently resuspended, and obtains inclusion body.SDS-
PAGE electrophoretic analysis purity of protein, if renaturation can be reached and require (purity > 80%).
Renaturing inclusion bodies:
Oxalate oxidase inclusion body uses rapid dilution method renaturation: washing qualified solubilization of inclusion bodies in 8M urea liquid
In, after measuring protein concentration, 1ml/min is at the uniform velocity added drop-wise to rapid dilution renaturation, final concentration of protein in the renaturation solution of pre-cooling and is
100 μ g/ml, magnetic agitation mixing are placed on 4 DEG C of renaturation for 24 hours.Renaturation solution formula be it is set forth below any one:
1. 20mM Tris,300mM NaCl,1mM MnCl2,1mM GSH/0.2mM GSSG,pH8.0
2. 20mM Tris,300mM NaCl,1mM MnCl2,1mM GSH/0.2mM GSSG,400mM arginine,
pH8.0
3. 20mM Tris,300mM NaCl,1mM MnCl2,1mM GSH/0.2mM GSSG,100mM α-
cyclodextrin,pH8.0
4. 20mM Tris,300mM NaCl,1mM MnCl2, 1mM GSH/0.2mM GSSG, 2% β-
cyclodextrin,pH8.0
5. 20mM Tris,300mM NaCl,1mM MnCl2, 1mM GSH/0.2mM GSSG, 40%sucrose,
pH8.0
6. 20mM Tris,300mM NaCl,1mM MnCl2, 1mM GSH/0.2mM GSSG, 40%glucose, pH
8.0
7. 20mM Tris,1mM MnCl2,1mM GSH/0.2mM GSSG,pH8.0
8. 20mM Tris,1mM MnCl2,1mM GSH/0.2mM GSSG,400mM arginine,pH8.0
9. 20mM Tris,1mM MnCl2,1mM GSH/0.2mM GSSG,50mM betaine,pH8.0
10. 20mM Tris,1mM MnCl2,50mM betaine,pH8.0
11. 20mM Tris,0.5-5mM MnCl2,1mM GSH/0.2mM GSSG,50mM betaine,pH8.0
12. 20mM Tris,1mM MnCl2,1mM GSH/0.2mM GSSG,50mM betaine,pH4.0-10.0
13. 20mM Tris,1mM MnCl2,50mM betaine,0.05mM 1-hexanol,50mM acetamide,
300mM KCl,pH8.0
Refolded protein is through phenyl sepharose purifying resin, and vigor is up to 0.1~15U/mg albumen.
Initialism:
1, GSH glutathione 6, sucrose sucrose
2, GSSG oxidized form of glutathione 7, glucose glucose
3, Arginine arginine 8, betaine glycine betaine
4, α-cyclodextrin alpha-cyclodextrin 9, hexanol hexanol
5, β-cyclodextrin beta-cyclodextrin 10, acetamide acetamide
[embodiment 4] Bichi yeast system expresses oxalate oxidase
(1) vector construction
By B5100, B5102, B5601, M30640 gene is cloned by Xho I and Not I restriction enzyme site into pPICZ α B
And pGAPZ α A carrier, the recombinant plasmid of building are Z α -5102, GAPZ α -5102, Z α -5601, GAPZ α -5601, Z α -
30640 (Fig. 1~5).Recombinant plasmid Z α -5102, Z α -30640, Z α -5601 are linearized with Pme I (Mss I) restriction endonuclease,
GAPZa-B5102, GAPZ α -5601, GAPZ α -30640 are linearized with Bln I (Avr II).Carrier after linearisation is logical
Electricity is crossed to turn mode and convert Pichia pastoris X33 strain to be expressed.
Table 2. constructs pPICZ α B and pGAPZ α A expression vector Primer and sequence
PCR system (50ul):
PCR program:
(2) protein expression
With YPDS culture medium (10g/L yeast powder, 20g/L peptone, 20g/L glucose, 1M sorbierite, 20g/L agar,
Containing 100 μ g/L zeocin antibiotic) positive colony of plate screening, then the YPDS plate (1mg/ml with high concentration antibiotic
Zeocin the screening of copy number) is carried out, the clone of the high copy number screened is expressed with shaking flask to be verified.
The YPD culture medium of the clone access 4mL of Z α -5102, Z α -30640, the Z α -5601 of the high copy screened, 28
DEG C culture 18~20h, by 4% inoculum concentration switching 500ml shaking flask (culture medium containing 50ml) expression culture medium BMGY (yeast powder
1% (w/v), peptone 2% (w/v), 100mM kaliumphosphate buffer pH 6.0, no amino yeast nitrogen 1.34% (w/v) are sweet
1% (w/v) of oil, biotin 0.04% (w/v)), 28 DEG C, after 220rpm grows 18~20h, OD6003.0~6.0 are reached, centrifugation
BMMY culture medium (yeast powder 1% (w/v), peptone 2% (w/v), 100mM kaliumphosphate buffer at are resuspended in after collecting thallus
PH 6.0, no amino yeast nitrogen 1.34% (w/v), 1.0% (v/v) methanol, biotin 0.04% (w/v), 5mM MnCl2)
Carry out inducing expression.Inducing expression temperature is 28 DEG C, adds methanol daily to final concentration of 1.0%, 90~120h of continuous induction.
Culture takes supernatant for determination of color oxalate oxidase vigor and SDS-PAGE identification and analysis after 9500g is centrifuged.
The GAPZa-B5102 of the high copy screened, GAPZ α -5601, GAPZ α -30640 bacterial strain, switching are cultivated in BYPD
Base (10g/l yeast powder, 20g/l peptone, 20g/l glucose, biotin 400 μ g/l, MnCl25mM and 100mM phosphoric acid
Potassium buffer, pH 6.0), 28 DEG C, 220rpm shake culture adds 2% glucose after 48h, after cultivating 72h, collects culture
Object centrifugation, supernatant are analyzed for oxalate oxidase vitality test and SDS-PAGE.
The results show that four kinds of oxalate oxidases (B5100, B5102, B5601, M30640) can in Yeast system at
Function expression, yield are 0.01~0.1mg/ml culture medium, and SDS-PAGE is analysis shows that purpose band is 24KD (Fig. 6~9), colour developing
The test of method vigor shows that it has oxalic acid degradation vigor at pH7.4.
[embodiment 5] botanical system expresses oxalate oxidase
(1) vector construction
By B5102, B5601, M30640 gene introduces Xba I and Kpn I restriction enzyme site by PCR amplification, then through this
PHTE carrier is inserted into two sites, obtains pHTE-5601, pHTE-5102 and pHTE-30640 (Figure 10).Positive restructuring matter
Grain is transferred in Agrobacterium tumefaciems GV3101 after bacterium solution PCR and endonuclease digestion verifying with freeze thawing recovery method.
Table 3 constructs plant expression vector Primer and sequence
PCR system (50 μ l):
PCR program:
(2) transformation of tobacco blade carries out transient expression
This uncured tobacco of wild type (N.benthamiana) (16/8h illumination/dark, 25 DEG C) in greenhouse is cultivated 5~8 weeks.
Conversion there are into B5102, B5601, the Agrobacterium strain of M30640 gene is inoculated in (rifampin containing 25mg/L in 3ml LB culture medium
And the kanamycins of 50mg/L), 28 DEG C, 220rpm is incubated overnight to OD600> 1.2 are used as seed liquor.Seed liquor is in 1:100 ratio
It accesses 2L LB culture medium (rifampin containing 25mg/L, 20 μM of acetosyringones of 50mg/L kanamycins and), 220rpm, 28 DEG C
It cultivates to OD600For 0.8~1.2 (about 18h).5000rpm is centrifuged 5min, removes supernatant, the bacterium of 5 times of volumes of bacterial sediment
Re-suspension liquid (10mM 2- (N- morpholine) ethane sulfonic acid sodium (MES) pH 5.5,10mM MgSO4And 100mM acetosyringone),
Incubated at room temperature 4h.
Agrobacterium bacterium solution is injected in tobacco leaf by 1ml or 3ml syringe and is infected, each injection point is generally about
Having 7 square centimeters of range can be infected to each blade need to infect several points.Plant after infecting is placed in a greenhouse growth 7
Normal watering and fertilising is given once daily in it or so.
(3) blade oxalate oxidase vigor test experiments
The tobacco leaf cultivated 7 days after infecting is harvested for the test of oxalate oxidase vigor.Test method are as follows: infection court
Surrounding vanes (containing negative control group) are cut to the discoid of diameter about 1cm, are centrifuged after vanes high-speed homogenization, supernatant precipitating
Be placed in oxalate oxidase vitality test buffer (40mM succinic acid, 2.5mM oxalic acid, 5U/ml horseradish peroxidase,
The chloro- 1- naphthols of 0.6mg/ml 4-, 60% (V/V) ethyl alcohol, pH 5.0), it is incubated at room temperature colour developing overnight, does not show enzyme activity in supernatant,
Oxalate oxidase vigor is presented in precipitating.
It similarly infects method and infects expression experiment for pea seedlings.
Two kinds of expression systems of tobacco and pea the results show that for expression 3 oxalate oxidase genes all have grass
Acid oxidase vigor (Figure 11, Figure 12), expression quantity are about the fresh blade of 0.01~5mg/g, but the overwhelming majority grass expressed
Acid oxidase is present in the solid material of blade, insoluble or cannot effectively dissolve out.
The vigor test of [embodiment 6] oxalate oxidase (Bacillus coli expression) under different ph values
Test method:
10 μ l oxalate oxidase solutions be added to 190 μ l vigor test solution in (800mg/L 4-AA,
4.8mM sodium 3,5-dichloro-2-hydroxybenzenesulfonate, 10U/ml horseradish peroxidase, 5mM oxalic acid, different pH buffers), it mixes
37 DEG C of 10~60min of incubation are placed on, microplate reader reads OD492Light absorption value.
Different pH buffer compositions: the buffer of pH4.5~6.0 selects the citrate buffer solution of 50mM, and pH6.0~8.0 is selected
With the phosphate buffer of 50mM.
Test result shows that the maximum vigor of oxalate oxidase 5100 is 18.2U/mg, and 5102 maximum vigor are 19.5U/mg,
5601 maximum vigor are 18.7U/mg, and 30640 maximum vigor are 14U/mg.Compare for convenience, we are by four kinds of enzymes in difference
Vigor under pH value is scaled relative activity and arranges into table 3:
The opposite Rate activity at various ph values of 3 four kinds of oxalate oxidases of table
The PEGylated modification of [embodiment 7] oxalate oxidase
The washing of oxalate oxidase inclusion body:
Bacillus coli cells with wash buffer (50mM Tris, 50mM NaCl, 5mM EDTA, 5mM DTT, 1%
TritonX-100,2M urea are sufficiently resuspended (concentration about 30g/L) with hydrochloric acid tune pH8.0), nucleic acid then are added according to 1:1000
Enzyme (benzonase, the MgCl of final concentration of 0.5mM2), stir 15min, the thinning laggard horizontal high voltage homogeneous of bacterium solution.It is high-pressure homogeneous
Condition be 1100bar, repeatedly be crushed 4 times.The centrifugation of clasmatosis liquid, 8000g, 10min abandon supernatant, collect precipitating.
Inclusion body cleaning:Inclusion body is sufficiently resuspended with suitable wash buffer, stir about 30min, 8000g centrifugation
10min abandons supernatant and collects precipitating, washs repeatedly and inclusion body is resuspended with pure water afterwards three times, and 8000g is centrifuged 10min after being sufficiently resuspended,
Obtained inclusion body weighing, SDS-PAGE analyze inclusion body protein purity, if can reach renaturation and require (purity > 80%).
Q column denaturation purifying oxalate oxidase inclusion body:
The qualified inclusion body (purity > 80%) of washing is dissolved in 8M urea liquid (20mM Tris-HCl, 8M urea, pH
8.0), 13000g is centrifuged 10min, discards precipitating, supernatant loading and the Q column (5 column volumes of equilibrium liquid balance) balanced, with washing
De- liquid B (8M urea, 30g/L NaCl, Tris-HCl, pH8.0) elution 6 column volumes (CV) elutes impurity protein, uses elution instead
Liquid C (8M urea, 160g/L NaCl, Tris-HCl, pH8.0) elution, collects target sample peak, through Q column purification, oxalic acid oxidation
For enzyme inclusion body protein purity up to 95%, sample after purification is concentrated into renaturation reality of the 5mg/ml for next step with super filter tube
It tests.
Oxalate oxidase inclusion body protein renaturation
It is operated by being described in embodiment 3.
Phenyl sepharose purifying resin
Before loading, Phenyl sepharose column is flat with equilibrium liquid (10mM Tris-HCl, 500mM NaCl, pH 8.0)
Weigh 5 column volumes (CV).NaCl to final concentration of 0.5M is added in oxalate oxidase B5102 after renaturation, 0.45 μ is crossed after mixing
The filter membrane of m is clarified.Clarified solution loading and the Phenyl sepharose pillar balanced, with wash buffer (10mM Tris-
HCl, 250mM NaCl, pH 8.0) use instead after 1.5 column volumes of washing eluent (10mM Tris-HCl, 20%
Isopropanol, pH 7.0) elution.Target protein sample peak is collected, and NaCl to 50mM is added to carry out salt precipitation, after saltouing
Sample is centrifuged 10min through 12000g, discards supernatant, and precipitating is redissolved in borate buffer (10mM Na2B4O7~H3BO3,pH
9.0) the PEGylated modification in, for the later period.It purifies obtained sample and carries out SDS-PAGE analysis purity of protein, oxalate oxidase
Vigor test evaluation renaturation effect.
The PEGylated modification of oxalate oxidase
The oxalate oxidase B5102 albumen borate buffer for being dissolved in borate solution adjusts concentration to 2mg/ml.It presses
10 multiple proportions column investment mPEG-SC (the Methoxy PEG Succinimidyl of the molal quantity of lysine on B5102 albumen
Carboxymethyl Ester) modifier carries out PEGylated modification reaction into the B5102 protein solution of mild magnetic agitation, it mixes
28 DEG C of reaction 6h after even are added the glycine equal with mPEG mole and terminate reaction.We tested 2kD, 5kD, 10kD,
The PEG modifier of 4 arm -40kD of 20kD, 4 arm -20kD, 30kD, 40kD and.
PEG modification after B5102 sample with molecular-exclusion chromatography (GE HiLoad Superdex 16/600GL, USA) into
Row isolates and purifies.Molecular-exclusion chromatography uses phosphate buffer (10mM K before loading2HPO4~KH2PO4, pH 7.4) carry out it is flat
Weigh 5 column volumes, carries out loading by the 5% of column volume, is then eluted again with phosphate buffer, flow velocity 1ml/min, collect sample
Product peak.
The oxalate oxidase of [embodiment 8] different molecular weight PEG modification reduces blood oxalic acid and urine oxalic acid in rat model
Experiment
30 5 week old SD male rats, weight is about 130~150g, is bought from Hubei Province's animal experimental center.Rat is raised
It supports and adapts to be randomized into rat generation after a week in independent gas supply cage (IVC) system (18~26 DEG C of temperature, humidity 40~70%)
It thanks in cage, is divided into 5 groups, wherein one group is control group, four groups are experimental group, every group of 6 rats.After the laundering period, control group
With the blood oxalic acid of experimental group rat and urine oxalic acid it is stable after, the oxalic acid of 3 kinds of different molecular weight PEG (20K, 30K, 40K) modification
Oxidase B 5102 is administered into different experimental group rats by tail vein injection mode, wherein one group of experimental group rat injects phase
For physiological saline with dose volume as placebo, drug administration dosage is 0.2mg/ days/time, successive administration 3 days, control group
Rat is not cooked any treatment processing.Control rats feed conventional mouse grain and drinking-water, and experimental group rat feeds conventional mouse grain and 1% second
Glycol drinking-water.After administration, the blood oxalic acid and urine oxalic acid of all rats carry out detection monitoring daily.It is acquired daily by tail vein
0.3ml blood collects serum after 5000g is centrifuged 5min, hydrochloric acid tune is added for measuring blood concentration of oxalic acid, freshly harvested blood
PH to 2.0~4.0 is saved, vitamin C in serum (Vc) is prevented to be converted into oxalic acid.The every 12h of urine (8:30am and 8:30pm) is collected
Once, and with salt acid for adjusting pH to 1.5~2.0, Vc is prevented to be converted into oxalic acid.The blood oxalic acid and urine oxalic acid of all rats are tested
It surveys, effect experiment can be carried out after stablizing.
The measurement of blood oxalic acid uses Amplex red (10-acetyl-3,7-dihydroxyphenoxazine) luciferase mark
Method detection, testing process are as follows:
(1) blood serum sample after hydrochloric acid acidification is centrifuged 30min ultrafiltration with 10K ultrafiltration membrane centrifuge tube 5000g and removes serum egg
It is white, 4 DEG C of temperature.
(2) ultrafiltrate is added in 96 hole fluorescence ELISA Plates (all black is opaque), 6 parallel holes of each sample spot, preceding 3
Oxalic acid reaction reagent (100mM citrate buffer solution, pH5.4,10 μM of Amplex red, 1U/mL HRP, 0.1U/ is added in a hole
ML oxalate oxidase), background calibration reagent (100mM citrate buffer solution, pH5.4,10 μM of Amplex are added in rear 3 holes
Red, 1U/mL HRP), 25 DEG C of incubation 30min after concussion mixes.
(3) fluorescent value is detected with fluorescence microplate reader (excitation wavelength: 538nm, wavelength of transmitted light: 590nm).
(4) according to the net fluorescent value of sample (oxalic acid test group Mean Fluorescence-background calibration group Mean Fluorescence) and oxalic acid
Standard curve fluorescent value is compareed, and the concentration of oxalic acid in sample is calculated.
The oxalic acid assay kit that concentration of oxalic acid measurement uses U.S. Trinity company is urinated, concrete operation step is strictly pressed
It is executed according to operational manual.
The results show that administration group (20K, 30K, 40K PEG-OxOx-B5102) can drop 40% compared with placebo
~50% blood concentration of oxalic acid, while 20%~40% urine concentration of oxalic acid dropping.(Figure 13 and Figure 14)
The measurement of [embodiment 9] PEG-OxOx immunogenicity
The B5102 sample of oxalate oxidase B5102 and different molecular weight PEG (2k, 5k, 10k, 20k, 30k, 40k) modification
Immunogenic evaluation is carried out by tail vein injection SD rat.Injection dosage is 0.2mg/ times, once a week, persistent immunological four
In week, different time points take blood serum sample to measure antibody titer, assessment immunogenicity (immune preceding 0 before immune for the first time and after immune
It, the 7th day, the 14th day, the 21st day, the 28th day, the 45th day, the 60th day).
It is as follows to measure process:
(1) with coating buffer (50mM carbonate/bicarbonate buffer, pH9.6) dilution PEG modification
B5102 protein sample is put in 96 hole elisa Plates holes of the supreme absorption of 100 μ l to 10 μ g/ml, is placed in 4 DEG C overnight with masking foil package
Coating.
(2) coating plate is placed in room temperature, empties liquid and pats dry residual liquid, with 300 μ l cleaning solution (1.5mM KH2PO4;
8.1mM Na2HPO4·12H2O;136mM NaCl;2.7mM KCl;It 0.05%Tween-20) cleans twice.
(3) each 300 μ l confining liquid (1.5mM KH of Kong Zhongjia2PO4;8.1mM Na2HPO4·12H2O;136mM NaCl;
2.7mM KCl;5% skimmed milk power), it is incubated for 1h.
(4) it empties liquid and pats dry residual liquid, cleaned twice with 300 μ l eluents.
(5) blood serum sample (50 times, 100 times, 200 times, 400 times, 800 times ... ...) of gradient dilution are done with cleaning solution to mix
After even plus 100 μ l are into every enzyme mark hole, 37 DEG C of incubation 1h or incubation at room temperature 3h.
(6) it empties liquid and pats dry residual liquid, cleaning solution is filled it up in each hole, empty liquid and pat dry residual liquid,
It is repeated 3 times.
(7) with cleaning solution by the goat anti rat antibody (secondary antibody) that HRP is coupled be diluted to optimal concentration (generally 1/5000~
1/20000) 100 μ l secondary antibodies, and into each instrument connection are added, are incubated at room temperature 1h.
(8) it empties liquid and pats dry residual liquid, eluent is filled it up in each hole, empty liquid and pat dry residual liquid,
It repeats 3~5 times.
(9) by 6ml TMB reagent A (0.5mM EDTA-Na;5mM citric acid;10% glycerol;0.04%tetramethyl
) and 6ml reagent B (165mM sodium acetate benzidine;8.3mM citric acid;0.06%30%-H2O2) mix.
(10) each 100 μ l TMB developing solution of Kong Zhongjia, after being incubated at room temperature 30min, each 100 μ l of Kong Zhongjia terminates reaction
Liquid (2M H2SO4)。
(11) microplate reader measures OD450Light absorption value.
The results show that the antibody titer of oxalate oxidase reached peak at the 28th day.28th day result (Figure 15)
Oxalate oxidase is shown after PEG is modified, the antibody titer of oxalate oxidase is remarkably decreased, and with modification PEG molecular weight
Increase, fall is bigger, 20k, 30k, and the oxalate oxidase of 40kPEG modification is nearly no detectable antibody.
SEQUENCE LISTING
<110>Wuhan Kangfude Biotechnology Co., Ltd.
<120>a kind of oxalate oxidase great-hearted under physiological ph conditions and its application
<160> 34
<170> PatentIn version 3.3
<210> 1
<211> 651
<212> DNA
<213> beet stem
<400> 1
tctgatcctg gtctcctaca ggatttttgt gtgggtgtaa atgaccctga ttcagcagtg 60
tttgtaaatg gaaaattctg caagaaccca aaagacgtga caatcgacga tttcttatac 120
aaagggttta atattccctc agacacaaac aacactcaaa gagcagaagc cacactagta 180
gatgtcaatc gatttccagc acttaacaca ttaggtgtag ccatggctcg tgtagacttt 240
gcgtcctttg gcctaaacac acctcatttg caccctcgtg gttctgagat attcgcggtg 300
ctagagggga ctttatatgc cggcattgtc accaccgatt acaagctttt cgacacggtg 360
ttgagaaagg gtgacatgat tgttttccct caaggcttaa tccacttcca gcttaatctt 420
ggcaagacag atgctcttgc tattgcctct tttgggagcc aatttcctgg acgagttaat 480
gttgctaatg gtgtctttgg aactacgcca caaattttgg atgatgtact tacccaagcg 540
tttcaggtag atgagatggt gattcagcaa cttcgatctc agttttcagg tcaaaacata 600
tcaatcaaca ctggaagatc tattcttaaa ctcttaactg atgttgcttg a 651
<210> 2
<211> 651
<212> DNA
<213> beet stem
<400> 2
tctgatcctg gtctcctaca ggatttttgt gtgggtgtaa atgaccctga ttcagcagtg 60
tttgtaaatg gaaaattctg caagaaccca aaagacgtga caatcgacga tttcttatac 120
aaagggttta atattccctc agacacaaac aacactcaaa gagcagaagc cacactagta 180
gatgtcaatc gatttccagc acttaacaca ttaggtgtag ccatggctcg tgtagacttt 240
gcgtcctttg gcctaaacac acctcatttg caccctcgtg gttctgagat attcgcggtc 300
ctagagggga ctttatatgc cggcattgtc accaccgata ataagctttt cgacacggtg 360
ttgagaaagg gtgacatgat tgttttccct caaggcttaa tccacttcca gcttaatctt 420
ggcaagacag atgctcttgc tattgcctct tttgggagcc aatttcctgg acgagttaat 480
gttgctaatg gtgtctttgg aactacgcca caaattttgg atgatgtact tacccaagcg 540
tttcaggtag ataagatggt gattgagcaa cttcgatctc agttttcagg tccaaacaca 600
tcaatcaaca ctggaagatc tattcttaaa ctcttaactg atgttgcttg a 651
<210> 3
<211> 651
<212> DNA
<213> beet stem
<400> 3
tccgatcctg caccccttca agatttttgt attgctgtaa atgatcccaa ttctgcagtg 60
cttgtgaatg gaaagctttg taagaaccca aaagaagtga caatagatga tttcttgtac 120
aaagggttta atatacctgc agacacaaac aacactcaag gagcaagtgc cacactagtg 180
gacattactc tattccctgc agttaacaca caaggagtct ccatggctcg tgtggacttt 240
gcgccatttg gactaaacac ccctcattta catcctcgtg gctcagaggt tttcgcagtg 300
atggaaggga ttatgtatgc tggttttgtg accactgatt ataagctcta tgatacaatt 360
ataaaaaagg gtgatattat tgtgtttcca caaggtctaa ttcatttcca acttaatctt 420
gggaagacag atgctttagc aattgcctca tttgggagcc aaaatccagg gagaattaat 480
atcgctgaca gtgtgtttgg tactactccg cgtgttctag atgatgtgct taccaaagga 540
tttcaaatcg atgagttgtt ggtcaagcaa cttcgttctc agttttctac tgataatata 600
tcaacaagca ctggaaggtc atttttgaaa ttgctatctg aaacttattg a 651
<210> 4
<211> 642
<212> DNA
<213> banana peel
<400> 4
tttgatccga gtcctctcca agacttttgc gttgctgact acgactccaa cgtgtttgtg 60
aacggattcg cctgcaagaa agctaaggat gtcacggcag atgacttcta cttcaccggc 120
ttagacaagc ccgcgagcac cgccaacgag cttggcgcaa acatcactct cgtcaacgtg 180
gaacgactcc caggcctcaa ctcccttggc gtcgccatgt ctcgcatcga ctacgcgccc 240
ttcggtctca accctcctca ctcgcatcca cgatcgtcgg agatactgca cgtggcggaa 300
ggaacgctct acgccggctt cgtcacctcc aacacggaaa acggcaacct tctcttcgct 360
aagaagctga agaagggcga cgcgtttgtg ttccccaggg gcctcataca cttccagttc 420
aacatcgggg acaccgatgc ggtggcgttc gctaccttcg gcagccagag cccgggtctc 480
gtcaccaccg ccaacgcact gttcggatcg aagccgccca tcgctgatta cattcttgcc 540
caggccgtgc agcttagcaa gacgaccgtg ggctggcttc agcagcagca gtggttggac 600
atcgctcaag aatatggaca acgcttagtt caagctaatt ga 642
<210> 5
<211> 216
<212> PRT
<213> beet stem
<400> 5
Ser Asp Pro Gly Leu Leu Gln Asp Phe Cys Val Gly Val Asn Asp Pro
1 5 10 15
Asp Ser Ala Val Phe Val Asn Gly Lys Phe Cys Lys Asn Pro Lys Asp
20 25 30
Val Thr Ile Asp Asp Phe Leu Tyr Lys Gly Phe Asn Ile Pro Ser Asp
35 40 45
Thr Asn Asn Thr Gln Arg Ala Glu Ala Thr Leu Val Asp Val Asn Arg
50 55 60
Phe Pro Ala Leu Asn Thr Leu Gly Val Ala Met Ala Arg Val Asp Phe
65 70 75 80
Ala Ser Phe Gly Leu Asn Thr Pro His Leu His Pro Arg Gly Ser Glu
85 90 95
Ile Phe Ala Val Leu Glu Gly Thr Leu Tyr Ala Gly Ile Val Thr Thr
100 105 110
Asp Tyr Lys Leu Phe Asp Thr Val Leu Arg Lys Gly Asp Met Ile Val
115 120 125
Phe Pro Gln Gly Leu Ile His Phe Gln Leu Asn Leu Gly Lys Thr Asp
130 135 140
Ala Leu Ala Ile Ala Ser Phe Gly Ser Gln Phe Pro Gly Arg Val Asn
145 150 155 160
Val Ala Asn Gly Val Phe Gly Thr Thr Pro Gln Ile Leu Asp Asp Val
165 170 175
Leu Thr Gln Ala Phe Gln Val Asp Glu Met Val Ile Gln Gln Leu Arg
180 185 190
Ser Gln Phe Ser Gly Gln Asn Ile Ser Ile Asn Thr Gly Arg Ser Ile
195 200 205
Leu Lys Leu Leu Thr Asp Val Ala
210 215
<210> 6
<211> 216
<212> PRT
<213> beet stem
<400> 6
Ser Asp Pro Gly Leu Leu Gln Asp Phe Cys Val Gly Val Asn Asp Pro
1 5 10 15
Asp Ser Ala Val Phe Val Asn Gly Lys Phe Cys Lys Asn Pro Lys Asp
20 25 30
Val Thr Ile Asp Asp Phe Leu Tyr Lys Gly Phe Asn Ile Pro Ser Asp
35 40 45
Thr Asn Asn Thr Gln Arg Ala Glu Ala Thr Leu Val Asp Val Asn Arg
50 55 60
Phe Pro Ala Leu Asn Thr Leu Gly Val Ala Met Ala Arg Val Asp Phe
65 70 75 80
Ala Ser Phe Gly Leu Asn Thr Pro His Leu His Pro Arg Gly Ser Glu
85 90 95
Ile Phe Ala Val Leu Glu Gly Thr Leu Tyr Ala Gly Ile Val Thr Thr
100 105 110
Asp Asn Lys Leu Phe Asp Thr Val Leu Arg Lys Gly Asp Met Ile Val
115 120 125
Phe Pro Gln Gly Leu Ile His Phe Gln Leu Asn Leu Gly Lys Thr Asp
130 135 140
Ala Leu Ala Ile Ala Ser Phe Gly Ser Gln Phe Pro Gly Arg Val Asn
145 150 155 160
Val Ala Asn Gly Val Phe Gly Thr Thr Pro Gln Ile Leu Asp Asp Val
165 170 175
Leu Thr Gln Ala Phe Gln Val Asp Lys Met Val Ile Glu Gln Leu Arg
180 185 190
Ser Gln Phe Ser Gly Pro Asn Thr Ser Ile Asn Thr Gly Arg Ser Ile
195 200 205
Leu Lys Leu Leu Thr Asp Val Ala
210 215
<210> 7
<211> 216
<212> PRT
<213> beet stem
<400> 7
Ser Asp Pro Ala Pro Leu Gln Asp Phe Cys Ile Ala Val Asn Asp Pro
1 5 10 15
Asn Ser Ala Val Leu Val Asn Gly Lys Leu Cys Lys Asn Pro Lys Glu
20 25 30
Val Thr Ile Asp Asp Phe Leu Tyr Lys Gly Phe Asn Ile Pro Ala Asp
35 40 45
Thr Asn Asn Thr Gln Gly Ala Ser Ala Thr Leu Val Asp Ile Thr Leu
50 55 60
Phe Pro Ala Val Asn Thr Gln Gly Val Ser Met Ala Arg Val Asp Phe
65 70 75 80
Ala Pro Phe Gly Leu Asn Thr Pro His Leu His Pro Arg Gly Ser Glu
85 90 95
Val Phe Ala Val Met Glu Gly Ile Met Tyr Ala Gly Phe Val Thr Thr
100 105 110
Asp Tyr Lys Leu Tyr Asp Thr Ile Ile Lys Lys Gly Asp Ile Ile Val
115 120 125
Phe Pro Gln Gly Leu Ile His Phe Gln Leu Asn Leu Gly Lys Thr Asp
130 135 140
Ala Leu Ala Ile Ala Ser Phe Gly Ser Gln Asn Pro Gly Arg Ile Asn
145 150 155 160
Ile Ala Asp Ser Val Phe Gly Thr Thr Pro Arg Val Leu Asp Asp Val
165 170 175
Leu Thr Lys Gly Phe Gln Ile Asp Glu Leu Leu Val Lys Gln Leu Arg
180 185 190
Ser Gln Phe Ser Thr Asp Asn Ile Ser Thr Ser Thr Gly Arg Ser Phe
195 200 205
Leu Lys Leu Leu Ser Glu Thr Tyr
210 215
<210> 8
<211> 213
<212> PRT
<213> banana peel
<400> 8
Phe Asp Pro Ser Pro Leu Gln Asp Phe Cys Val Ala Asp Tyr Asp Ser
1 5 10 15
Asn Val Phe Val Asn Gly Phe Ala Cys Lys Lys Ala Lys Asp Val Thr
20 25 30
Ala Asp Asp Phe Tyr Phe Thr Gly Leu Asp Lys Pro Ala Ser Thr Ala
35 40 45
Asn Glu Leu Gly Ala Asn Ile Thr Leu Val Asn Val Glu Arg Leu Pro
50 55 60
Gly Leu Asn Ser Leu Gly Val Ala Met Ser Arg Ile Asp Tyr Ala Pro
65 70 75 80
Phe Gly Leu Asn Pro Pro His Ser His Pro Arg Ser Ser Glu Ile Leu
85 90 95
His Val Ala Glu Gly Thr Leu Tyr Ala Gly Phe Val Thr Ser Asn Thr
100 105 110
Glu Asn Gly Asn Leu Leu Phe Ala Lys Lys Leu Lys Lys Gly Asp Ala
115 120 125
Phe Val Phe Pro Arg Gly Leu Ile His Phe Gln Phe Asn Ile Gly Asp
130 135 140
Thr Asp Ala Val Ala Phe Ala Thr Phe Gly Ser Gln Ser Pro Gly Leu
145 150 155 160
Val Thr Thr Ala Asn Ala Leu Phe Gly Ser Lys Pro Pro Ile Ala Asp
165 170 175
Tyr Ile Leu Ala Gln Ala Val Gln Leu Ser Lys Thr Thr Val Gly Trp
180 185 190
Leu Gln Gln Gln Gln Trp Leu Asp Ile Ala Gln Glu Tyr Gly Gln Arg
195 200 205
Leu Val Gln Ala Asn
210
<210> 9
<211> 639
<212> DNA
<213> germin-like
<400> 9
atggctcccc tactctacct tgtagtattc ttgcttgctc cttttctctc ccatgctgcg 60
gatcccgatc ctttgctaga tttttgtgta gcggacctta atgcctctcc ctcatttgct 120
aatttccctt gcaaacaaac ctcaaatgtg acctctgaag atttcttctt tgatgggttt 180
atgaatgagg gaaacacatc aaactcgttt ggatcaaggg tcacacccgg aaacgtcctc 240
acatttcctg cccttaatat gctcgggatt tcaatgaatc gggttgatct tgctgtggat 300
gggatgaacc cgccccattc ccacccacga gcaagtgaga gcggtgtggt gatgaagggg 360
agagttctag tagggttcgt aaccacgggg aatgtgtact attcaaaggt gttggttcca 420
ggacagatgt ttgtaatccc aagggggttg gttcattttc aaaagaatgt tggacaaaat 480
aaggcactca tcattacagc tttcaatagt cagaatccag gagtagtgtt attatcctca 540
accctgtttg gtacaaaccc ttcaattcca gatgatgttt taagccaaac tttcctagtg 600
gaccagagca ttgtcgaagg aataaaatcc aacttttga 639
<210> 10
<211> 718
<212> DNA
<213> germin-like
<400> 10
atggaagtcg tcgcagctgt atcttttctg gccgtgttat tggctctggt ttcccctgcc 60
ctcgccaatg atcctgatat cttttctggc cgtgttattg gctctggttt cccctgccct 120
cgccaatgat cctgatatgc tccaagatgt ttgtgtcgct gattccacct ctggagtgaa 180
attgaatgga tttgcatgca aggatgcagc aagcattaca ccagaagact tcttctttgc 240
tggaatatcc aaacccggaa tgacaaacaa tacaatgaaa tccctagtaa ccggagctaa 300
cgtcgaaaag ataccgggtt taaacacact cggagtgtcc atgggtcgta tcgacttcgg 360
cccaggtggt cttaacccac ctcacactca cccacgagcc acagaaatgg tctttgtgtt 420
atatggagaa ttggacgttg gtttcctaac tacttctaat aagctcattt ctaagcatat 480
taaaactggt gaaacttttg tttttcctag agggttagtc cactttcaga aaaataatgg 540
ggataaacct gctgctttag tcactgcttt taatagtcag ttgcctggca cccaatcaat 600
agctgccacg ttgtttacgt cgaccccacc tgttccagat aatgttttaa ctatgacttt 660
ccaagtcggt actaaacaag tccagaagat caaggctagg ctcgctccta agaagtaa 718
<210> 11
<211> 669
<212> DNA
<213> germin-like
<400> 11
atggcggctg tttgggtagt cttggtggtg ctagcggcgg cttttgctgt tggggtcttt 60
gccagcgatc ctgatatgct tcaagatgtt tgtgttgctg atcgtacatc tggaatatta 120
gtgaatggat tcacatgtaa aaatatgacc atgataaccc ctgaagactt cttcttcacc 180
ggaatttcac aaccaggcca aatcacaaat aaaatccttg gttctcgagt caccggagcg 240
aatgtgcagg acatccctgg tctcaacacc ttgggagtct cgatggctcg tgtcgacttt 300
actccctacg gtctaaaccc acctcacatt caccctagaa tcgtccaccc tcgtgccact 360
gaaatgatct atgttcttaa gggtgaattg tacgttggtt ttataacgac cgacaataag 420
ctcatttcca aggttgttaa agctggagaa gtatttgttt tccctagagg tttggctcac 480
tttcagaaaa acatgttgaa atatccagct gctgcattag ctgccttcaa cagccaactt 540
ccaggcactc aacaatttgc agctgctctc tttacttcca atcctcctgt gtctaatgat 600
gtgttggctc aggcttttaa cattgacgaa cacaatgtca aaaagattag ggctggcctt 660
actccatag 669
<210> 12
<211> 660
<212> DNA
<213> germin-like
<400> 12
atggagtcgc actacacgaa gagaccattc ctcctctttc tctccttcac cgtcctcctc 60
gtgttgatcc gcgctgaccc tgatcctctc caggacttct gcgtcgccga cctcggagct 120
actgtggtcg tcaatgggtt cccgtgcaag cccgcgtccg gagtcacgtc cgacgacttc 180
ttcttcgccg gactgtccag ggagggcaac accagcaata tcttcgggtc caacgtgacc 240
aacgccaaca tgctcagctt cccggggctc aacaccctcg gcgtctccat gaaccgcgtc 300
gacgtcgccc ccggcggcac caacccgccc cacagccacc cgagggctac cgagctcatc 360
atcctcctca agggccggct gctggtgggg ttcatcagca ccagtaacca gttcttctcc 420
aaggtcttga accccggcga gatgttcgtg gtgcccaagg ggctcatcca cttccagtac 480
aacgtcggca aggagaaggc gctcgccatc accaccttcg acagccagct ccccggagta 540
gtgatcgcct ccaccaccct gttcgcatcg aatccggcga ttcccgacga tgtgctggcc 600
aaagcttttc aggtggacgc gaaggtcgtc gctctcatca agtccaagtt tgagagataa 660
<210> 13
<211> 212
<212> PRT
<213> germin-like
<400> 13
Met Ala Pro Leu Leu Tyr Leu Val Val Phe Leu Leu Ala Pro Phe Leu
1 5 10 15
Ser His Ala Ala Asp Pro Asp Pro Leu Leu Asp Phe Cys Val Ala Asp
20 25 30
Leu Asn Ala Ser Pro Ser Phe Ala Asn Phe Pro Cys Lys Gln Thr Ser
35 40 45
Asn Val Thr Ser Glu Asp Phe Phe Phe Asp Gly Phe Met Asn Glu Gly
50 55 60
Asn Thr Ser Asn Ser Phe Gly Ser Arg Val Thr Pro Gly Asn Val Leu
65 70 75 80
Thr Phe Pro Ala Leu Asn Met Leu Gly Ile Ser Met Asn Arg Val Asp
85 90 95
Leu Ala Val Asp Gly Met Asn Pro Pro His Ser His Pro Arg Ala Ser
100 105 110
Glu Ser Gly Val Val Met Lys Gly Arg Val Leu Val Gly Phe Val Thr
115 120 125
Thr Gly Asn Val Tyr Tyr Ser Lys Val Leu Val Pro Gly Gln Met Phe
130 135 140
Val Ile Pro Arg Gly Leu Val His Phe Gln Lys Asn Val Gly Gln Asn
145 150 155 160
Lys Ala Leu Ile Ile Thr Ala Phe Asn Ser Gln Asn Pro Gly Val Val
165 170 175
Leu Leu Ser Ser Thr Leu Phe Gly Thr Asn Pro Ser Ile Pro Asp Asp
180 185 190
Val Leu Ser Gln Thr Phe Leu Val Asp Gln Ser Ile Val Glu Gly Ile
195 200 205
Lys Ser Asn Phe
210
<210> 14
<211> 219
<212> PRT
<213> germin-like
<400> 14
Met Glu Val Val Ala Ala Val Ser Phe Leu Ala Val Leu Leu Ala Leu
1 5 10 15
Val Ser Pro Ala Leu Ala Asn Asp Pro Asp Met Leu Gln Asp Val Cys
20 25 30
Val Ala Asp Ser Thr Ser Gly Val Lys Leu Asn Gly Phe Ala Cys Lys
35 40 45
Asp Ala Ala Ser Ile Thr Pro Glu Asp Phe Phe Phe Ala Gly Ile Ser
50 55 60
Lys Pro Gly Met Thr Asn Asn Thr Met Lys Ser Leu Val Thr Gly Ala
65 70 75 80
Asn Val Glu Lys Ile Pro Gly Leu Asn Thr Leu Gly Val Ser Met Gly
85 90 95
Arg Ile Asp Phe Gly Pro Gly Gly Leu Asn Pro Pro His Thr His Pro
100 105 110
Arg Ala Thr Glu Met Val Phe Val Leu Tyr Gly Glu Leu Asp Val Gly
115 120 125
Phe Leu Thr Thr Ser Asn Lys Leu Ile Ser Lys His Ile Lys Thr Gly
130 135 140
Glu Thr Phe Val Phe Pro Arg Gly Leu Val His Phe Gln Lys Asn Asn
145 150 155 160
Gly Asp Lys Pro Ala Ala Leu Val Thr Ala Phe Asn Ser Gln Leu Pro
165 170 175
Gly Thr Gln Ser Ile Ala Ala Thr Leu Phe Thr Ser Thr Pro Pro Val
180 185 190
Pro Asp Asn Val Leu Thr Met Thr Phe Gln Val Gly Thr Lys Gln Val
195 200 205
Gln Lys Ile Lys Ala Arg Leu Ala Pro Lys Lys
210 215
<210> 15
<211> 217
<212> PRT
<213> germin-like
<400> 15
Met Ala Ala Val Trp Val Val Leu Val Val Leu Ala Ala Ala Phe Ala
1 5 10 15
Val Gly Val Phe Ala Ser Asp Pro Asp Met Leu Gln Asp Val Cys Val
20 25 30
Ala Asp Arg Thr Ser Gly Ile Leu Val Asn Gly Phe Thr Cys Lys Asn
35 40 45
Met Thr Met Ile Thr Pro Glu Asp Phe Phe Phe Thr Gly Ile Ser Gln
50 55 60
Pro Gly Gln Ile Thr Asn Lys Ile Leu Gly Ser Arg Val Thr Gly Ala
65 70 75 80
Asn Val Gln Asp Ile Pro Gly Leu Asn Thr Leu Gly Val Ser Met Ala
85 90 95
Arg Val Asp Phe Thr Pro Tyr Gly Leu Asn Pro Pro His Ile His Pro
100 105 110
Arg Ala Thr Glu Met Ile Tyr Val Leu Lys Gly Glu Leu Tyr Val Gly
115 120 125
Phe Ile Thr Thr Asp Asn Lys Leu Ile Ser Lys Val Val Lys Ala Gly
130 135 140
Glu Val Phe Val Phe Pro Arg Gly Leu Ala His Phe Gln Lys Asn Met
145 150 155 160
Leu Lys Tyr Pro Ala Ala Ala Leu Ala Ala Phe Asn Ser Gln Leu Pro
165 170 175
Gly Thr Gln Gln Phe Ala Ala Ala Leu Phe Thr Ser Asn Pro Pro Val
180 185 190
Ser Asn Asp Val Leu Ala Gln Ala Phe Asn Ile Asp Glu His Asn Val
195 200 205
Lys Lys Ile Arg Ala Gly Leu Thr Pro
210 215
<210> 16
<211> 219
<212> PRT
<213> germin-like
<400> 16
Met Glu Ser His Tyr Thr Lys Arg Pro Phe Leu Leu Phe Leu Ser Phe
1 5 10 15
Thr Val Leu Leu Val Leu Ile Arg Ala Asp Pro Asp Pro Leu Gln Asp
20 25 30
Phe Cys Val Ala Asp Leu Gly Ala Thr Val Val Val Asn Gly Phe Pro
35 40 45
Cys Lys Pro Ala Ser Gly Val Thr Ser Asp Asp Phe Phe Phe Ala Gly
50 55 60
Leu Ser Arg Glu Gly Asn Thr Ser Asn Ile Phe Gly Ser Asn Val Thr
65 70 75 80
Asn Ala Asn Met Leu Ser Phe Pro Gly Leu Asn Thr Leu Gly Val Ser
85 90 95
Met Asn Arg Val Asp Val Ala Pro Gly Gly Thr Asn Pro Pro His Ser
100 105 110
His Pro Arg Ala Thr Glu Leu Ile Ile Leu Leu Lys Gly Arg Leu Leu
115 120 125
Val Gly Phe Ile Ser Thr Ser Asn Gln Phe Phe Ser Lys Val Leu Asn
130 135 140
Pro Gly Glu Met Phe Val Val Pro Lys Gly Leu Ile His Phe Gln Tyr
145 150 155 160
Asn Val Gly Lys Glu Lys Ala Leu Ala Ile Thr Thr Phe Asp Ser Gln
165 170 175
Leu Pro Gly Val Val Ile Ala Ser Thr Thr Leu Phe Ala Ser Asn Pro
180 185 190
Ala Ile Pro Asp Asp Val Leu Ala Lys Ala Phe Gln Val Asp Ala Lys
195 200 205
Val Val Ala Leu Ile Lys Ser Lys Phe Glu Arg
210 215
<210> 17
<211> 25
<212> DNA
<213> Artificial
<223> B5100/5102F
<400> 17
atgtctgatc ctggtctcct acagg 25
<210> 18
<211> 24
<212> DNA
<213> Artificial
<223> B5100/5102R
<400> 18
agcaacatca gttaagagtt taag 24
<210> 19
<211> 25
<212> DNA
<213> Artificial
<223> B5601F
<400> 19
atgtccgatc ctgcacccct tcaag 25
<210> 20
<211> 20
<212> DNA
<213> Artificial
<223> B5601R
<400> 20
tcaataagtt tcagatagca 20
<210> 21
<211> 25
<212> DNA
<213> Artificial
<223> M30640F
<400> 21
atgtttgatc cgagtcctct ccaag 25
<210> 22
<211> 25
<212> DNA
<213> Artificial
<223> M30640R
<400> 22
tcaattagct tgaactaagc gttgt 25
<210> 23
<211> 36
<212> DNA
<213> Artificial
<223>Bichi yeast system B5102F
<400> 23
ccgctcgaga aaagatctga tcctggtctc ctacag 36
<210> 24
<211> 37
<212> DNA
<213> Artificial
<223>Bichi yeast system B5102R
<400> 24
aaatatgcgg ccgctcaagc aacatcagtt aagagtt 37
<210> 25
<211> 33
<212> DNA
<213> Artificial
<223>Bichi yeast system B5601F
<400> 25
ccgctcgaga aaagatccga tcctgcaccc ctt 33
<210> 26
<211> 39
<212> DNA
<213> Artificial
<223>Bichi yeast system B5601R
<400> 26
aaatatgcgg ccgctcaata agtttcagat agcaatttc 39
<210> 27
<211> 35
<212> DNA
<213> Artificial
<223>Bichi yeast system M30640f
<400> 27
ccgctcgaga aaagatttga tccgagtcct ctcca 35
<210> 28
<211> 38
<212> DNA
<213> Artificial
<223>Bichi yeast system M30640R
<400> 28
aaatatgcgg ccgctcaatt agcttgaact aagcgttg 38
<210> 29
<211> 33
<212> DNA
<213> Artificial
<223>plant expression system 5102-F
<400> 29
gctctagaat gtctgatcct ggtctcctac agg 33
<210> 30
<211> 34
<212> DNA
<213> Artificial
<223>plant expression system 5102-R
<400> 30
cggggtacct caagcaacat cagttaagag ttta 34
<210> 31
<211> 34
<212> DNA
<213> Artificial
<223>plant expression system 5601-R
<400> 31
gctctagaat gtccgatcct gcaccccttc aaga 34
<210> 32
<211> 34
<212> DNA
<213> Artificial
<223>plant expression system 5601-R
<400> 32
cggggtacct caataagttt cagatagcaa tttc 34
<210> 33
<211> 33
<212> DNA
<213> Artificial
<223>plant expression system 30640-F
<400> 33
gctctagaat gtttgatccg agtcctctcc aag 33
<210> 34
<211> 34
<212> DNA
<213> Artificial
<223>plant expression system 30640-R
<400> 34
cggggtacct caattagctt gaactaagcg ttgt 34
Claims (10)
1. a kind of oxalate oxidase, can degrade oxalic acid or oxalates under physiological ph conditions, it is characterised in that: its gene order
As shown in SEQ ID NO. 3.
2. oxalate oxidase described in claim 1, it is characterised in that: be the polyethyleneglycol modified oxalic acid oxygen of different molecular weight
Change enzyme.
3. oxalate oxidase according to claim 2, it is characterised in that: the molecular weight of the polyethylene glycol is 2kD,
Any one in 5kD, 10kD, 20kD, 4 arm -20kD, 30kD, 40kD or 4 arm -40kD.
4. a kind of expression vector includes the gene order in claim 1.
5. a kind of recombinant strains include expression vector as claimed in claim 4, can produce grass described in claim 1
Acid oxidase.
The oxalic acid of oxalic acid or oxalates 6. expression vector as claimed in claim 4 can degrade under the conditions of physiological pH is expressed in building
Application in oxidizing ferment genetically modified plants.
7. oxalate oxidase of any of claims 1-3 reduces oxalosis disease patient concentration of oxalic acid in preparation
Drug in application.
8. application as claimed in claim 7, it is characterised in that: the oxalosis disease is primary hyperoxaluria,
Two type hyperoxalurias, zellweger disease or chronic urinary system damageability disease.
9. a kind of pharmaceutical composition comprising recombinating oxalate oxidase described in claim 1-3 any one.
10. pharmaceutical composition as claimed in claim 9, it is characterised in that: injection is made or is embedded through enteric material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710607474.6A CN107299089B (en) | 2014-12-22 | 2015-02-10 | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410804796 | 2014-12-22 | ||
CN201510069577.2A CN104673765B (en) | 2014-12-22 | 2015-02-10 | One group of great-hearted oxalate oxidase and its application under physiological ph conditions |
CN201710607474.6A CN107299089B (en) | 2014-12-22 | 2015-02-10 | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510069577.2A Division CN104673765B (en) | 2014-12-22 | 2015-02-10 | One group of great-hearted oxalate oxidase and its application under physiological ph conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107299089A CN107299089A (en) | 2017-10-27 |
CN107299089B true CN107299089B (en) | 2019-09-17 |
Family
ID=53309359
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510069577.2A Active CN104673765B (en) | 2014-12-22 | 2015-02-10 | One group of great-hearted oxalate oxidase and its application under physiological ph conditions |
CN201710606904.2A Active CN107254453B (en) | 2014-12-22 | 2015-02-10 | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application |
CN201710607474.6A Active CN107299089B (en) | 2014-12-22 | 2015-02-10 | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510069577.2A Active CN104673765B (en) | 2014-12-22 | 2015-02-10 | One group of great-hearted oxalate oxidase and its application under physiological ph conditions |
CN201710606904.2A Active CN107254453B (en) | 2014-12-22 | 2015-02-10 | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN104673765B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106906227B (en) * | 2017-03-08 | 2020-02-21 | 武汉康复得生物科技股份有限公司 | Preparation method and application of soluble oxalate oxidase |
EP3728649A1 (en) * | 2017-12-22 | 2020-10-28 | DuPont Nutrition Biosciences ApS | New lactic acid bacteria with sweetening properties and uses thereof |
CA3089284A1 (en) * | 2018-02-28 | 2019-09-06 | The Procter & Gamble Company | Methods of cleaning using a glycogen debranching enzyme |
CN108342400B (en) * | 2018-03-05 | 2021-04-06 | 武汉康复得生物科技股份有限公司 | Genetic engineering bacterium for recombinant expression of oxalate oxidase and construction method and application thereof |
US10751399B2 (en) * | 2018-03-20 | 2020-08-25 | Cho Pharma Usa, Inc. | Chimeric antigen receptors that bind to SSEA4 and uses thereof |
CN109022471B (en) * | 2018-08-01 | 2021-07-20 | 武汉康复得生物科技股份有限公司 | Escherichia coli expression system for producing oxalate oxidase, and production method and application of oxalate oxidase |
CN110387360B (en) * | 2019-06-18 | 2021-12-28 | 华东理工大学 | Hydroxysteroid dehydrogenase and application thereof in synthesis of ursodeoxycholic acid precursor |
US20220403437A1 (en) * | 2019-10-17 | 2022-12-22 | Osaka University | Glucuronosyltransferase, gene encoding same and method for using the same |
CN114019165B (en) * | 2022-01-05 | 2022-04-01 | 首都医科大学附属北京妇产医院 | Polypeptide chip or kit and application thereof in diagnosing non-small cell lung cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321640A (en) * | 2011-08-18 | 2012-01-18 | 杭州瑞丰生物科技有限公司 | Herbicide resistant gene, and application of herbicide resistant gene in genetically modified crops |
CN102329785A (en) * | 2011-10-28 | 2012-01-25 | 武汉新华扬生物股份有限公司 | Medium-temperature alkali-resistant mannase Man5XH9 and gene and application thereof |
CN103911296A (en) * | 2014-04-21 | 2014-07-09 | 山东大学 | Penicillium oxalicum strain for increasing enzyme activities of cellulase and hemicellulase |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0239237B2 (en) * | 1984-05-21 | 1990-09-04 | Noda Sangyo Kagaku Kenkyusho | SHUSANOKISHIDAAZENOSEIZOHO |
CN100383239C (en) * | 2004-07-21 | 2008-04-23 | 华南农业大学 | Process for extracting oxalate oxidase from bran of wheat |
CN101554237B (en) * | 2009-03-16 | 2013-11-06 | 武汉康复得生物科技有限公司 | Preparation method of oxalate-degrading enzyme contained in plant fiber or microorganism indissolvable component |
ES2617917T3 (en) * | 2009-07-02 | 2017-06-20 | Oxthera Intellectual Property Ab | Purification and isolation of recombinant oxalate degradation enzymes and spray-dried particles containing oxalate degradation enzymes |
CN102725403A (en) * | 2009-11-25 | 2012-10-10 | 凯普托杰姆有限责任公司 | Methods and compositions for treating oxalate-related conditions |
-
2015
- 2015-02-10 CN CN201510069577.2A patent/CN104673765B/en active Active
- 2015-02-10 CN CN201710606904.2A patent/CN107254453B/en active Active
- 2015-02-10 CN CN201710607474.6A patent/CN107299089B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102321640A (en) * | 2011-08-18 | 2012-01-18 | 杭州瑞丰生物科技有限公司 | Herbicide resistant gene, and application of herbicide resistant gene in genetically modified crops |
CN102329785A (en) * | 2011-10-28 | 2012-01-25 | 武汉新华扬生物股份有限公司 | Medium-temperature alkali-resistant mannase Man5XH9 and gene and application thereof |
CN103911296A (en) * | 2014-04-21 | 2014-07-09 | 山东大学 | Penicillium oxalicum strain for increasing enzyme activities of cellulase and hemicellulase |
Also Published As
Publication number | Publication date |
---|---|
CN107254453A (en) | 2017-10-17 |
CN104673765A (en) | 2015-06-03 |
CN104673765B (en) | 2017-11-17 |
CN107254453B (en) | 2019-10-25 |
CN107299089A (en) | 2017-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107299089B (en) | A kind of oxalate oxidase great-hearted under physiological ph conditions and its application | |
EP3087178B1 (en) | Method for producing oxalate oxidases having activity optimum near physiological ph and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases | |
CN106282216B (en) | A kind of preparation method of recombinant long-acting chicken interferon α | |
EA018443B1 (en) | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions | |
CN103272225A (en) | Crystallized oxalate decarboxylase and methods of use | |
CN113512096B (en) | Weever rhabdovirus recombinant G2 protein and application thereof | |
CN101955545A (en) | Multi-target recombination gene and application of protein thereof in preventing and treating infection of helicobacter pylori | |
CN109694833A (en) | Lactobacillus germ and its anti-trioxypurine improve allergy and hypoglycemic purposes | |
Bákonyi et al. | Chemical traits of fermented alfalfa brown juice: Its implications on physiological, biochemical, anatomical, and growth parameters of Celosia | |
CN107098974A (en) | A kind of fusion protein and its application | |
WO2015002588A1 (en) | Secretagogues derived from oxalobacter formigenes | |
CN105647943A (en) | Saussurea involucrata cell squalene synthase (SiSQS) gene as well as products coded by same and application thereof | |
CN109694832A (en) | Lactobacillus germ and its reducing blood lipid, liver function index, uric acid and anti-inflammatory purposes | |
Daniell et al. | Affordable oral proinsulin bioencapsulated in plant cells regulates blood sugar levels similar to natural insulin | |
CN102604993B (en) | Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof | |
CN107576791A (en) | One boar lawsonia intracellularis ELISA detection kit | |
CN103848914A (en) | Bufrudin polypeptide with anticoagulant activity and preparation method and purpose thereof | |
CN104862331B (en) | A kind of method of solubility expression Rhodococcus equi Disease-causing gene VapA albumen | |
CN109207499A (en) | Key gene IbPAL1 and application in sweet potato chlorogenic acid route of synthesis | |
CN113940993B (en) | Perch rhabdovirus G2-2M subunit vaccine and preparation method thereof | |
CN110923289B (en) | Screening method of drug for treating citrus greening disease | |
CN111171144B (en) | Preparation and application of antibody for resisting porcine epidemic diarrhea virus | |
CN100575488C (en) | Utilize the method for plant oil-body expression human metal thioalbumen | |
CN103936864B (en) | A kind of porcine growth hormone fusion protein and application thereof | |
CN109006917A (en) | Wheat catalase is improving the application in flour processing quality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |